Literature DB >> 23702390

Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.

Shini-ichi Tobisawa1, Masaru Honma, Akemi Ishida-Yamamoto, Yasuaki Saijo, Hajime Iizuka.   

Abstract

BACKGROUND: The analysis of prognostic factors in Japanese cases of cutaneous T-cell lymphoma (CTCL) is scarce. Clusterin is a ubiquitous 80kDa heterodimeric glycoprotein expressed on tumor cells of systemic and primary cutaneous anaplastic large cell lymphoma. The expression of clusterin in mycosis fungoides (MF) and Sézary syndrome (SS) has only been sporadically reported in a small number of cases.
OBJECTIVE: To determine the long-term prognosis of Japanese patients with MF and SS, to identify clinical and pathological factors predictive of survival, and to evaluate the prognostic significance of the International Society for Cutaneous Lymphomas (ISCL) revised staging system (2007).
METHODS: We performed a retrospective cohort study of 105 Japanese patients with MF and SS managed at the Department of Dermatology Asahikawa Medical University from 1976 to 2011. Formalin-fixed, paraffin-embedded sections of MF and SS were immunostained for clusterin, CD30, and Ki-67.
RESULTS: No statistically significant difference in survival was found between stages IA-IIA and IIIA patients. The significant prognostic factors in the univariate analysis were higher age, TNMB classification, clinical staging, performance status, increased serum LDH level, dermal Ki-67-positive cells, and clusterin expression. In the multivariate analysis, T classification, extracutaneous disease, increased serum LDH level, clusterin expression, and performance status were the significant independent prognostic factors.
CONCLUSION: Japanese stage IIIA MF/SS patients contain a subpopulation with a favorable prognosis. The most significant prognostic factor for survival of MF and SS was the presence of extracutaneous disease. Clusterin expression was shown to be a novel unfavorable prognostic factor.
Copyright © 2013 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Clusterin; Cutaneous T-cell lymphoma; Mycosis fungoides; Prognosis; Sézary syndrome

Mesh:

Substances:

Year:  2013        PMID: 23702390     DOI: 10.1016/j.jdermsci.2013.04.020

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  5 in total

1.  Prognostic factors of patients with mycosis fungoides.

Authors:  Anıl Gülsel Bahalı; Ozlem Su; Fatma Pelin Cengiz; Nazan Emiroğlu; Dilek Bıyık Ozkaya; Nahide Onsun
Journal:  Postepy Dermatol Alergol       Date:  2020-11-07       Impact factor: 1.837

2.  Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry Studies.

Authors:  Jianzhong Zhang; Chenkui Miao; Aiming Xu; Kai Zhao; Zhiqiang Qin; Xiao Li; Chao Liang; Yibo Hua; Wei Chen; Chao Zhang; Yiyang Liu; Shifeng Su; Zengjun Wang; Bianjiang Liu
Journal:  PLoS One       Date:  2016-08-17       Impact factor: 3.240

3.  Proteomic Profiling Change and Its Implies in the Early Mycosis Fungoides (MF) Using Isobaric Tags for Relative and Absolute Quantification (iTRAQ).

Authors:  Mengyan Zhu; Yong Li; Cheng Ding; Jiaqi Wang; Yangyang Ma; Zhao Li; Xiaoyan Zhang; Ping Wang
Journal:  Biomed Res Int       Date:  2020-11-23       Impact factor: 3.411

4.  Investigation of proteomic profiles in canine lymphoma using tandem mass tag-based quantitative proteomics approach.

Authors:  Piyanoot Fonghem; Trairak Pisitkun; Kasem Rattanapinyopituk; Sirintra Sirivisoot; Anudep Rungsipipat
Journal:  Vet World       Date:  2022-05-26

5.  Assessment of lipocalin 2, clusterin, soluble tumor necrosis factor receptor-1, interleukin-6, homocysteine, and uric acid levels in patients with psoriasis.

Authors:  Arzu Ataseven; Recep Kesli; Gulcan Saylam Kurtipek; Perihan Ozturk
Journal:  Dis Markers       Date:  2014-04-02       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.